文献速递精神分裂症与精神病性障碍

精神分裂症患者氯氮平使用与长期死亡风险的人群研究

Population-based study of long-term mortality risk associated with clozapine use among patients with schizophrenia.
PubMed 文献 · Br J Psychiatry · 2025-07-04

这项18年人群队列研究纳入香港精神分裂症患者9456例,比较连续或非连续使用氯氮平者与匹配的非氯氮平抗精神病药使用者。调整模型显示,连续使用氯氮平者自杀死亡风险较低,连续使用且联用其他抗精神病药者自杀及全因死亡风险均较低,其他死因未见关联。

要点

  • 连续使用氯氮平者自杀死亡风险显著低于连续使用非氯氮平者。
  • 连续使用氯氮平并联用其他抗精神病药者自杀和全因死亡风险更低。
  • 氯氮平与心血管病、感染、癌症等特定死因未见显著关联。

核心结论

  • 连续使用氯氮平与精神分裂症患者较低的自杀死亡风险相关。
  • 连续使用氯氮平并联用其他抗精神病药与较低的自杀和全因死亡风险相关。
  • 氯氮平与其他特定死因(心血管病、感染、癌症)无显著关联。

研究设计与样本

  • 18年基于人群的队列研究,检索香港所有公立医院精神分裂症患者电子健康记录。
  • 氯氮平使用者为2003至2012年起始氯氮平治疗者,对照为从未使用氯氮平者,按1:2倾向评分匹配人口学及躯体精神共病。
  • 共纳入9456例,平均年龄39.13岁(s.d.=12.92),女性50.73%,中位随访12.37年(IQR 9.78-15.22)。
  • 分组包括连续氯氮平使用者2020例、非连续氯氮平使用者1132例、连续非氯氮平使用者4326例、非连续非氯氮平使用者1978例。
  • 采用加速失效时间(AFT)模型估计全因及特定死因死亡风险。

主要发现

  • 连续氯氮平使用者相比连续非氯氮平使用者,自杀死亡加速因子为3.01(99% CI 1.41-6.44)。
  • 连续氯氮平使用者联用其他抗精神病药者相比连续非氯氮平使用者,自杀死亡加速因子为3.67(99% CI 1.41-9.60),全因死亡加速因子为1.42(99% CI 1.07-1.88)。
  • 氯氮平与其他特定死因(自杀、心血管病、感染、癌症)未见显著关联。

关键数值与推荐

  • 连续氯氮平使用者自杀死亡加速因子3.01(99% CI 1.41-6.44),对比连续非氯氮平使用者。
  • 连续氯氮平联用其他抗精神病药者自杀死亡加速因子3.67(99% CI 1.41-9.60),全因死亡加速因子1.42(99% CI 1.07-1.88),对比连续非氯氮平使用者。

临床怎么用

  • 对合适的难治性精神分裂症患者,应强调持续使用氯氮平以降低自杀死亡风险。
  • 氯氮平联用其他抗精神病药可能带来额外获益,但需结合个体情况评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with schizophrenia have a significantly elevated risk of mortality. Clozapine is effective for treatment-resistant schizophrenia, but its use is limited by side-effects. Understanding its association with mortality risk is crucial. AIMS: To investigate the associations of clozapine with all-cause and cause-specific mortality risk in schizophrenia patients. METHOD: In this 18-year population-based cohort study, we retrieved electronic health records of schizophrenia patients from all public hospitals in Hong Kong. Clozapine users (ClozUs) comprised schizophrenia patients who initiated clozapine treatment between 2003 and 2012, with the index date set at clozapine initiation. Comparators were non-clozapine antipsychotic users (Non-ClozUs) with the same diagnosis who had never received a clozapine prescription. They were 1:2 propensity score matched with demographic characteristics and physical and psychiatric comorbidities. ClozUs were further defined according to continuation of clozapine use and co-prescription of other antipsychotics (polypharmacy). Accelerated failure time (AFT) models were used to estimate the risk of all-cause and cause-specific mortality (i.e. suicide, cardiovascular disease, infection and cancer). RESULTS: This study included 9,456 individuals (mean (s.d.) age at the index date: 39.13 (12.92) years; 50.73% females; median (interquartile range) follow-up time: 12.37 (9.78-15.22) years), with 2020 continuous ClozUs, 1132 discontinuous ClozUs, 4326 continuous non-ClozUs and 1978 discontinuous Non-ClozUs. Results from adjusted AFT models showed that continuous ClozUs had a lower risk of suicide mortality (acceleration factor 3.01; 99% CI: 1.41-6.44) compared with continuous Non-ClozUs. Continuous ClozUs with co-prescription of other antipsychotics exhibited lower risks of suicide mortality (acceleration factor 3.67; 1.41-9.60) and all-cause mortality (acceleration factor 1.42; 1.07-1.88) compared with continuous Non-ClozUs. No associations were found between clozapine and other cause-specific mortalities. CONCLUSIONS: These results add to the existing evidence on the effectiveness of clozapine, particularly its anti-suicide effects, and emphasise the need for continuous clozapine use for suitable patients and the possible benefit of clozapine polypharmacy.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Zhou H, Luo H, Tang JY, et al. Population-based study of long-term mortality risk associated with clozapine use among patients with schizophrenia. Br J Psychiatry. 2025. PMID: 40611596. doi:10.1192/bjp.2025.10312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。